000288867 001__ 288867
000288867 005__ 20251023134511.0
000288867 0247_ $$2doi$$a10.1093/neuonc/noae049
000288867 0247_ $$2pmid$$apmid:38466087
000288867 0247_ $$2ISSN$$a1522-8517
000288867 0247_ $$2ISSN$$a1523-5866
000288867 0247_ $$2altmetric$$aaltmetric:160675588
000288867 037__ $$aDKFZ-2024-00514
000288867 041__ $$aEnglish
000288867 082__ $$a610
000288867 1001_ $$00000-0002-2485-1796$$aGalldiks, Norbert$$b0
000288867 245__ $$aChallenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group.
000288867 260__ $$aOxford$$bOxford Univ. Press$$c2024
000288867 3367_ $$2DRIVER$$aarticle
000288867 3367_ $$2DataCite$$aOutput Types/Journal article
000288867 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1720430728_6946
000288867 3367_ $$2BibTeX$$aARTICLE
000288867 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288867 3367_ $$00$$2EndNote$$aJournal Article
000288867 500__ $$a2024 Jul 5;26(7):1181-1194
000288867 520__ $$aBrain tumor diagnostics have significantly evolved with the use of PET and advanced MRI techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the RANO group, the EANO, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g., MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
000288867 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000288867 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288867 650_7 $$2Other$$aCEST
000288867 650_7 $$2Other$$aMR spectroscopy
000288867 650_7 $$2Other$$aamino acid PET
000288867 650_7 $$2Other$$adiffusion-weighted imaging
000288867 650_7 $$2Other$$aperfusion-weighted imaging
000288867 7001_ $$aKaufmann, Timothy J$$b1
000288867 7001_ $$aVollmuth, Philipp$$b2
000288867 7001_ $$00000-0002-5360-046X$$aLohmann, Philipp$$b3
000288867 7001_ $$00000-0001-5563-2871$$aSmits, Marion$$b4
000288867 7001_ $$aVeronesi, Michael C$$b5
000288867 7001_ $$aLangen, Karl-Josef$$b6
000288867 7001_ $$aRudá, Roberta$$b7
000288867 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b8
000288867 7001_ $$aHattingen, Elke$$b9
000288867 7001_ $$aLaw, Ian$$b10
000288867 7001_ $$aHutterer, Markus$$b11
000288867 7001_ $$00000-0002-9204-7038$$aSoffietti, Riccardo$$b12
000288867 7001_ $$aVogelbaum, Michael A$$b13
000288867 7001_ $$aWen, Patrick Y$$b14
000288867 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b15
000288867 7001_ $$0P:(DE-HGF)0$$aTonn, Joerg-Christian$$b16
000288867 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae049$$gp. noae049$$n7$$p1181-1194$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000288867 8564_ $$uhttps://inrepo02.dkfz.de/record/288867/files/noae049.pdf
000288867 8564_ $$uhttps://inrepo02.dkfz.de/record/288867/files/noae049.pdf?subformat=pdfa$$xpdfa
000288867 909CO $$ooai:inrepo02.dkfz.de:288867$$pVDB
000288867 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000288867 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000288867 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000288867 9141_ $$y2024
000288867 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000288867 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000288867 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000288867 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000288867 980__ $$ajournal
000288867 980__ $$aVDB
000288867 980__ $$aI:(DE-He78)MU01-20160331
000288867 980__ $$aUNRESTRICTED